Form 8-K PERNIX THERAPEUTICS HOLD For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics (PTX) Misses Q3 EPS by 19c
November 5, 2015 9:24 AM ESTPernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $46.83 million.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
... More